Targeting RPS6K1 for Refractory Breast Cancer Therapy
Article Sidebar
Main Article Content
ABSTRACT
In 2020, female breast cancer overtook lung cancer to become the most diagnosed cancer worldwide. Nearly 30% of women diagnosed with early-stage breast cancer have recurrent disease with resistance to therapeutics evidenced in 25% of cases. The hormone receptor positive (ER+ and PR+) and HER2+ breast cancers quickly develop resistance to the frontline therapeutics, namely, endocrine therapy and trastuzumab treatment. The overactivity of the PI3K/mTOR/S6K1 pathway has been shown to lead to multidrug resistant breast cancer. While PI3K and mTOR targeted therapeutics have shown promise, development of resistance and mutations in these proteins have limited the success of these agents. S6K1 kinase, a downstream effector whose activation leads to translation of ribosomal proteins, enhancement of mRNA biogenesis, and cap-dependent translation and elongation, is a critical player in the PI3K/mTOR pathway and the ER+ pathway. Inhibiting the activity of S6K1 can provide the needed therapeutic option for resistant/refractory breast cancer patients.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.